Would you like to help build the world’s best artificial heart – a technology that could save the lives of people suffering from severe heart failure? Scandinavian Real Heart (Realheart) is a Swedish company developing and manufacturing an artificial heart that mimics the anatomy and function of the human heart. In Västerås, where the company was originally founded, our team is working to take the technology from development to clinical reality. Realheart is listed on Nasdaq First North Growth and has recently announced its goal of being ready for implantation in its first patient in February 2028.
About the role
Realheart is strengthening its Engineering team ahead of the next stage in the company’s development. As a Mechanical Test Development Engineer, you will play an important role in developing test methods and equipment for a Total Artificial Heart.
This is an opportunity to join a company at the forefront of research within life-saving medical technology. You will contribute with your technical expertise in a collaborative team, where careful testing, continuous improvement and high-quality documentation are essential to moving development forward.
You will develop and implement test equipment and methods for medical devices, validate test methods, and perform testing within both R&D and production. The role involves close collaboration with cross-functional teams and internal and external stakeholders to ensure that testing is well planned, traceable and fit for purpose.
About you
You are an experienced engineer with a practical approach to test development and a strong interest in solving technical challenges. You are comfortable taking ownership of your work while enjoying close collaboration with colleagues from different disciplines. You have strong planning, prioritisation and coordination skills.
To succeed in the role, you combine analytical thinking with attention to detail and a structured way of working. You understand the importance of clear technical documentation, traceability and maintaining high-quality standards. You can plan, prioritise and coordinate your work effectively when several activities are running in parallel.
What we offer
You will become part of a growing team at a pivotal point in Realheart’s development. The role offers the chance to contribute directly to the continued development of advanced medical technology with the potential to make a meaningful difference for patients.
Here, you will work hands-on with test development while collaborating across functions and contributing to the methods and equipment needed for the next steps in the development journey. We welcome you to be a central member of our highly skilled and engaged team.
Application
We look forward to receiving your application. The application period runs from 18 September 2026 to 18 October 2026. For more information please feel welcome to contact Anna Nordanstig +46 70 306 55 64.
Interviews are conducted continuously, and the position may be filled before the closing date
Requirements
Preferred qualifications
About the Employer – Scandinavian Real Heart
Would you like to help build the world’s best artificial heart – a technology that could save the lives of people suffering from severe heart failure?
Scandinavian Real Heart AB is a Swedish MedTech company that develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a unique, patented design that resembles that of the natural human heart. Only about 8,000 heart transplants occur annually worldwide, and the availability of donated hearts is very limited. Realheart’s mission is to save as many patients who suffer from congestive heart disease as possible through this advanced MedTech solution. Realheart has a an extremely competent and engaged team placed in Västerås in Sweden and is also carried out in very close collaboration with world-leading heart surgeons and international researchers and engineers. In 2028 the goal is to be able to perform the first implantation in a human patient. Realheart is a public company listed on Nasdaq First North and has recently announced its goal of being ready for implantation in its first patient in February 2028.
